Results 41 to 50 of about 830,673 (331)

Clinical epidemiology of peritoneal metastases in China: The construction of professional peritoneal metastases treatment centers based on the prevalence rate.

European Journal of Surgical Oncology, 2022
OBJECTIVE To understand the tumor burden of peritoneal metastases (PM) in China, and to guide the construction of professional PM treatment centers in China.
Rui Yang, Yan-Hong Su, R. Ma, Yan Li
semanticscholar   +1 more source

Taurolidine reduces the tumor stimulating cytokine interleukin-1beta in patients with resectable gastrointestinal cancer : a multicentre prospective randomized trial [PDF]

, 2009
Background The effect of additional treatment strategies with antineoplastic agents on intraperitoneal tumor stimulating interleukin levels are unclear.
Willems Wilhelm, Scheele, Johannes, Gutt, Carsten Nils, Jacobi, Christoph A., Scheele Johannes, Menenakos Charalambos, Müller, Joachim M., Mueller Joachim M, Menenakos, Charalambos, Braumann Chris, Jacobi Christoph A, Willems, Wilhelm, Gutt Carsten N, Braumann, Chris   +13 more
core   +1 more source

Diagnosis of Peritoneal Metastases with Abdominal Malignancies: Role of ADC Measurement on Diffusion Weighted MRI

Eurasian Journal of Medicine, 2019
Objective: The purpose of our study was to evaluate the utility of the apparent diffusion coefficient (ADC) value measurement in the diagnosis of peritoneal metastases on diffusion weighted magnetic resonance imaging.
Mehmet Ruhi Onur, Muammer Akyol, Ahmet Kursad Poyraz, Ercan Kocakoc, Erkin Ogur   +4 more
doaj   +1 more source

Ascites and resistance to immune checkpoint inhibition in dMMR/MSI-H metastatic colorectal and gastric cancers

Journal for ImmunoTherapy of Cancer, 2022
Background Despite unprecedented benefit from immune checkpoint inhibitors (ICIs) in patients with mismatch repair deficient (dMMR)/microsatellite instability high (MSI-H) advanced gastrointestinal cancers, a relevant proportion of patients shows primary
Akihito Kawazoe, Kohei Shitara, Chiara Cremolini, Giovanni Fucà, Sara Lonardi, Filippo Pietrantonio, Francesca Corti, Samuel J Klempner, Magali Svrcek, Thierry André, Giuseppe Curigliano, Michael Overman, Francesca Bergamo, Elisabetta Fenocchio, Massimiliano Salati, Margherita Ambrosini, Giovanni Randon, Lisa Salvatore, Romain Cohen, Raphael Colle, Maria Elena Elez, Marwan Fakih, Aakash Tushar Shah, Joseph Chao, Matthew Emmett, Marc Díez García, Giacomo Mazzoli, Leonardo Provenzano, Keigo Chida, Veronica Conca   +29 more
doaj   +1 more source

Colorectal Cancer with Peritoneal Metastases: The Impact of the Results of PROPHYLOCHIP, COLOPEC, and PRODIGE 7 Trials on Peritoneal Disease Management

Cancers, 2022
Simple Summary Colorectal peritoneal metastases could potentially benefit from locoregional treatments such as cytoreduction combined with hyperthermic intraperitoneal chemotherapy (HIPEC).
A. Sommariva, M. Tonello, F. Coccolini, G. De Manzoni, P. Delrio, E. Pizzolato, R. Gelmini, F. Serra, Erion Rreka, E. Pasqual, L. Marano, D. Biacchi, F. Carboni, S. Kusamura, P. Sammartino   +14 more
semanticscholar   +1 more source

Surgical treatment of intraperitoneal metastases from lung cancer: two case reports and a review of the literature

Journal of Medical Case Reports, 2019
Background Peritoneal metastases are often reported in several abdominal tumors. Peritoneal diffusion from extra-abdominal tumors is thought to be rare. Lung cancer is one of the most common cancers in the world with early metastases and it is associated
Simone Sibio, Giuseppe Sigismondo Sica, Sara Di Carlo, Maurizio Cardi, Alessandra Di Giorgio, Bianca Maria Sollazzo, Paolo Sammartino   +6 more
doaj   +1 more source

Pressurised Intraperitoneal Aerosolised Chemotherapy (PIPAC) for gastric cancer with peritoneal metastases: A systematic review by the PIPAC UK Collaborative.

Critical reviews in oncology/hematology, 2022
INTRODUCTION Gastric cancer with peritoneal metastases (GCPM) carries a poor prognosis. Pressurised Intraperitoneal Aerosolised Chemotherapy (PIPAC) offers pharmacokinetic advantages over intravenous therapy, resulting in higher chemotherapy ...
A. Case, S. Prosser, C. Peters, R. Adams, S. Gwynne   +4 more
semanticscholar   +1 more source

Effect of Systemic or Intraperitoneal Administration of Anti-PD-1 Antibody for Peritoneal Metastases from Gastric Cancer

In Vivo, 2022
Background/Aim: Programmed death-1 (PD-1)/PD-ligand 1 (PD-L1) blockade therapy is widely used for the treatment of patients with metastatic gastric cancer (GC). However, it is unclear how PD-1 antibodies affect the local immunity related to the growth of
Yuko Kumagai, Yurie Futoh, H. Miyato, H. Ohzawa, H. Yamaguchi, Shin Saito, K. Kurashina, Y. Hosoya, A. Lefor, N. Sata, J. Kitayama   +10 more
semanticscholar   +1 more source

Intraperitoneal injection of class A TLR9 agonist enhances anti–PD-1 immunotherapy in colorectal peritoneal metastases

JCI Insight, 2022
Peritoneal metastases are associated with a low response rate to immune checkpoint blockade (ICB) therapy. The numbers of peritoneal resident macrophages (PRMs) are reversely correlated with the response rate to ICB therapy. We have previously shown that
Ting Jiang, Hongji Zhang, Yiming Li, Preethi Jayakumar, Hong Liao, Hai Huang, Timothy R. Billiar, Meihong Deng   +7 more
doaj   +1 more source

Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy for Gastric Cancer with Synchronous Peritoneal Metastases: Multicenter Study of ‘Italian Peritoneal Surface Malignancies Oncoteam—S.I.C.O.’

Annals of Surgical Oncology, 2021
The development of multimodality treatment, including cytoreductive surgery (CRS) with heated intraperitoneal chemotherapy (HIPEC), has led to promising results in selected patients with peritoneal disease of gastric origin.
L. Marano, D. Marrelli, P. Sammartino, D. Biacchi, L. Graziosi, E. Marino, F. Coccolini, P. Fugazzola, M. Valle, O. Federici, D. Baratti, M. Deraco, A. di Giorgio, A. Macrì, E. Pasqual, M. Framarini, M. Vaira, F. Roviello   +17 more
semanticscholar   +1 more source